{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:56:09Z","timestamp":1776329769070,"version":"3.50.1"},"reference-count":15,"publisher":"Baskent University","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.6002\/ect.2023.0252","type":"journal-issue","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T06:30:54Z","timestamp":1722234654000},"source":"Crossref","is-referenced-by-count":1,"title":[],"prefix":"10.6002","volume":"22","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Arena C, Bizzoca ME, Caponio VCA, et al. Everolimus therapy and side\u2011effects: a systematic review and meta\u2011analysis. Int Journal Oncol. 2021;59(1):54. doi:10.3892\/ijo.2021.5234","DOI":"10.3892\/ijo.2021.5234"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Fukushima N, Saito S, Sakata Y, Sawa Y. A case of everolimus-associated chylothorax in a cardiac transplant recipient. Transplant Proc. 2013;45(8):3144-3146. doi:10.1016\/j.transproceed.2013.08.082","DOI":"10.1016\/j.transproceed.2013.08.082"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Kazzaz F, O'Connell OJ, Vial MR, Stewart J, Grosu HB. Everolimus-induced chylous effusion. Am J Respir Crit Care Med. 2018;198(1):120-122. doi:10.1164\/rccm.201707-1438im","DOI":"10.1164\/rccm.201707-1438IM"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Cholet C, Delalandre C, Monnier-Cholley L, Le Pimpec-Barthes F, El Mouhadi S, Arriv\u00e9 L. Nontraumatic chylothorax: nonenhanced MR lymphography. Radiographics. 2020;40(6):1554-1573. doi:10.1148\/rg.2020200044","DOI":"10.1148\/rg.2020200044"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Meng LH, Zheng XF. Toward rapamycin analog (rapalog)-based precision cancer therapy. Acta Pharmacol Sin. 2015;36(10):1163-1169. doi:10.1038\/aps.2015.68","DOI":"10.1038\/aps.2015.68"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Fielhaber JA, Carroll SF, Dydensborg AB, et al. Inhibition of mammalian target of rapamycin augments lipopolysaccharide-induced lung injury and apoptosis. J Immunol. 2012;188(9):4535-4542. doi:10.4049\/jimmunol.1003655","DOI":"10.4049\/jimmunol.1003655"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Chen X, Hu C, Fan X, et al. mTOR inhibition promotes pneumonitis through inducing endothelial contraction and hyperpermeability. Am J Respir Cell Mol Biol. 2021;65(6):646-657. doi:10.1165\/rcmb.2020-0390OC","DOI":"10.1165\/rcmb.2020-0390OC"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Huber S, Bruns CJ, Schmid G, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int. 2007;71(8):771-777. doi:10.1038\/sj.ki.5002112.","DOI":"10.1038\/sj.ki.5002112"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Luo Y, Liu L, Rogers D, et al. Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression. Neoplasia. 2012;14(3):228-237. doi:10.1593\/neo.111570","DOI":"10.1593\/neo.111570"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Zhou H, Huang S. The complexes of mammalian target of rapamycin. Curr Protein Pept Sci. 2010;11(6):409-424. doi:10.2174\/138920310791824093","DOI":"10.2174\/138920310791824093"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Populo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13(2):1886-1918. doi:10.3390\/ijms13021886","DOI":"10.3390\/ijms13021886"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Sedrani R, Cottens S, Kallen J, Schuller W. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc. 1998;30(5):2192-2194. doi:10.1016\/s0041-1345(98)00587-9","DOI":"10.1016\/S0041-1345(98)00587-9"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf. 2015;14(7):1055-1070. doi:10.1517\/14740338.2015.1040388","DOI":"10.1517\/14740338.2015.1040388"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Jin YP, Valenzuela NM, Ziegler ME, Rozengurt E, Reed EF. Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus. Am J Transplant. 2014;14(4):806-819. doi:10.1111\/ajt.12669","DOI":"10.1111\/ajt.12669"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. doi:10.1038\/clpt.1981.154","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T06:50:32Z","timestamp":1722235832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/archive\/2024\/22\/6\/0\/471\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2023.0252","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}